ÜYE OL ÜYE GİRİŞ
ÜYE OLUN / GİRİŞ YAPIN
RxMediaPharma
KANSER İMMÜNOLOJİSİ

Moleküler Yolaklar

Normal hücreler, diğer hücresel streslerin yanı sıra


DNA hasarına yanıt olarak apoptozu başlatabilir.

Buna karşılık, kanser hücreleri genellikle benzer streslere karşı daha az hassastır ve apoptozdan kaçınma eğilimindedir.

PD-L1 Yolağı

PD-L1 yolağı inhibisyonunun temel alınması eş zamanlı olarak hedeflenebilen yolakları araştırarak kanser immünoterapisine ilişkin bilgileri arttırmaktadır

T Hücresi Bispesifikleri

T hücresi bispesifikleri, immün sistemin kanserle mücadele edecek duruma getirilmesine yönelik yenilikçi bir yöntemdir

Referanslar

  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. PMID: 21376230
  2. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274-284. PMID: 19308067
  3. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-252. PMID: 19279573
  4. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 2010;31:9-18. PMID: 19887512
  5. Ringshausen I, Peschel C, Decker T. Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery. Curr Drug Targets. 2006;7:1349-1359. PMID: 17073597
  6. Caldon CE, Sutherland RL, Musgrove EA. Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle. 2010;9:1918-1928. PMID: 20473028
  7. Sherr CJ. Principles of tumor suppression. Cell. 2004;116:235-246. PMID: 14744434
  8. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009;125:1747-1754. PMID: 19444916
  9. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol. 2008;84:988-993. PMID: 18515327
  10. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 2008;27:3889-3900. PMID: 18317452
  11. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836-848. PMID: 17063185
  12. Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci. 2001;114(pt 20):3591-3598. PMID: 11707511
  13. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027. PMID: 15585754
  14. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410. PMID: 12778130
  15. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23:537-548. PMID: 19270154
  16. Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol. 2011;38:70-86. PMID: 21362517
  17. Marie SK, Shinjo SM. Metabolism and brain cancer. Clinics (Sao Paulo). 2011;66(suppl 1):33-43. PMID: 21779721
  18. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4:139-163. PMID: 15725726
  19. Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8:121-132. PMID: 18202696
  20. Hermann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death Differ. 2006;13:1256-1259. PMID: 16710363
  21. Devarajan E, Sahin AA, Chen JS, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002;21:8843-8851. PMID: 12483536
  22. Quintavalle C, Donnarumma E, Iaboni M, et al. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene. 2013;32:4001-4008. PMID: 22964638
  23. Bardeesy N, Sharpless NE. RAS unplugged: negative feedback and oncogene-induced senescence. Cancer Cell. 2006;10:451-453. PMID: 17157783
  24. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev. 2010;20:65-71. PMID: 20036794